⌕
Vertex · VERX · Nasdaq
Tenet 26 · Weak
Compare
$18.40+2.39%At closeTenet 26 · Weak
$18.40+0.43 (+2.39%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Vertex (VERX) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● MarketBeatNov 16, 2026 · 07:12 ET
Vertex Pharmaceuticals Prepares for Key Kidney Drug Decision as Pipeline Readouts Loom

Vertex Pharmaceuticals NASDAQ: VRTX is preparing for a Nov. 30 U.S. regulatory decision on its kidney disease treatment povetacicept, while awaiting clinical results across kidney disease, chronic pain and other conditio…

● Seeking AlphaNov 13, 2026 · 05:35 ET
Maze Therapeutics: Vertex Is Building The Road, And Maze Gets To Drive On It

Maze Therapeutics, Inc. is positioned as the only APOL1 inhibitor competitor to Vertex, with strong Phase 2 data and funding into 2029. MAZE's HORIZON trial showed robust uACR reductions, especially in non-diabetic and s…

● The Motley FoolNov 11, 2026 · 15:40 ET
BioNTech vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?

BioNTech is aggressively pivoting its mRNA technology toward a deep pipeline of oncology treatments. Vertex Pharmaceuticals maintains high profitability and a dominant market share in cystic fibrosis therapies.…

● GlobeNewsWireNov 11, 2026 · 08:00 ET
Only One in Six Enterprises Treats Indirect Tax as a Standing Board Item

KING OF PRUSSIA, Pa., Nov. 11, 2026 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), the Decision-to-Defense™ global indirect tax and compliance company, today released the 2026 Vertex CompOps™…

● Zacks Investment ResearchNov 9, 2026 · 13:46 ET
Here is Why Growth Investors Should Buy Vertex (VERX) Now

Vertex (VERX) could produce exceptional returns because of its solid growth attributes.…

● The Motley FoolNov 7, 2026 · 09:37 ET
Bristol Myers Squibb vs. Vertex: Which Pharma Stock Is a Better Buy for 2027?

Bristol Myers Squibb is an established pharmaceutical powerhouse with a high-yield dividend and a focus on expanding its portfolio through strategic oncology alliances. Vertex Pharmaceuticals maintains a dominant positio…

● The Motley FoolNov 5, 2026 · 16:47 ET
Prediction: Vertex Pharmaceuticals Will Be 1 of the Best Biotech Stocks to Own Over the Next 5 Years

Vertex Pharmaceuticals' moat in cystic fibrosis remains nearly impregnable. The company's diversification efforts are slowly ramping up, and more is to come.…

● BenzingaNov 5, 2026 · 07:51 ET
Vertex Analysts Boost Their Forecasts After Better-Than-Expected Q3 Results

Vertex Inc (NASDAQ:VERX) on Wednesday reported better-than-expected third-quarter financial results and raised its FY26 sales guidance above estimates.…

● MarketBeatNov 5, 2026 · 04:17 ET
What Vertex (VERX) Said on Its Q3 Earnings Call

Vertex NASDAQ: VERX raised its full-year revenue and earnings guidance after reporting third-quarter revenue growth of 11% and a nearly 50% increase in adjusted earnings before interest, taxes, depreciation and amortizat…

● Seeking AlphaNov 5, 2026 · 02:54 ET
Vertex, Inc. (VERX) Q3 2026 Earnings Call Transcript

Vertex, Inc. (VERX) Q3 2026 Earnings Call Transcript…

● Zacks Investment ResearchNov 4, 2026 · 19:01 ET
Vertex (VERX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for Vertex (VERX) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street est…

● Zacks Investment ResearchNov 4, 2026 · 18:51 ET
Vertex (VERX) Surpasses Q3 Earnings and Revenue Estimates

Vertex (VERX) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of $0.22 per share. This compares to earnings of $0.17 per share a year ago.…

● GlobeNewsWireNov 4, 2026 · 16:03 ETCOMPANY'S OWN WORDS
Vertex Announces Third Quarter 2026 Financial Results

KING OF PRUSSIA, Pa., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), the Decision-to-Defense™ global indirect tax and compliance company, today announced financial results for …

● FXEmpireNov 4, 2026 · 06:22 ET
Vertex Pharmaceuticals Thrives on Higher Sales and Guidance

VRTX's Q3 fiscal 2027 revenue rose 12% YoY to $3.44B, driven by cystic fibrosis and new products like CASGEVY and PALSONIFY.…

● Zacks Investment ResearchNov 3, 2026 · 14:35 ET
Vertex Q3 Earnings Call Highlights Revenue Beat and Pipeline Expansion

VRTX beats Q3 revenue estimates and raises its 2026 outlook as CF therapies and newer drugs drive growth, but acquisition costs pressure earnings.…

● BenzingaNov 3, 2026 · 08:15 ET
Vertex Pharmaceuticals Analysts Raise Their Forecasts Following Q3 Results

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) reported mixed results for the third quarter on Monday.…

● MarketBeatNov 2, 2026 · 21:15 ET
Vertex Pharmaceuticals Q3 Earnings Call Highlights

Vertex Pharmaceuticals NASDAQ: VRTX reported third-quarter 2026 revenue growth of 12% year over year, supported by continued cystic fibrosis franchise growth and contributions from newer products including CASGEVY, JOURN…

● The Motley FoolNov 2, 2026 · 16:30 ET
Vertex Spends Its CF Growth on New Launches: Rapid Earnings Reaction

Alyftrek is replacing Trikafta, and that switch is still growing Vertex's cystic fibrosis franchise. Heavy spending on new launches and the Crinetics deal kept profit from rising with sales.…

● Business WireNov 2, 2026 · 16:01 ETCOMPANY'S OWN WORDS
Vertex Reports Third Quarter 2026 Financial Results

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter ended September 30, 2026, and raised its full year 2026 revenue guidance. “V…

● GlobeNewsWireNov 2, 2026 · 08:01 ET
Asure Software and Vertex Announce Strategic Alliance to Expand Payroll Tax Management Reach

AUSTIN, Texas, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Asure Software, Inc. (Nasdaq: ASUR), a leading provider of cloud-based Human Capital Management software and payroll tax management solutions, and Vertex, Inc. (NASDAQ:VER…

● Zacks Investment ResearchOct 27, 2026 · 12:16 ET
Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards?

VRTX is poised for a Q3 earnings beat as strong demand for Trikafta, Alyftrek's growth and rising Casgevy and Journavx sales drive expectations.…

● GlobeNewsWireOct 26, 2026 · 13:01 ETCOMPANY'S OWN WORDS
Vertex Introduces Vertex Sōl™, a Connected, AI-Powered Tax and Compliance Experience

Starting with the tax decision, Vertex Sōl connects the work, evidence, and AI that tax professionals control Starting with the tax decision, Vertex Sōl connects the work, evidence, and AI that tax professionals control…

● 24/7 Wall StreetOct 26, 2026 · 09:45 ET
The $500 Million Non-CF Factor Vertex Investors Can't Ignore on Nov. 2

Vertex Pharmaceuticals (NASDAQ:VRTX | VRTX Price Prediction) reports third-quarter results on Nov. 2. Cystic fibrosis still pays the bills, but I'll be watching whether CASGEVY and JOURNAVX stay on pace for management's …

● The Motley FoolOct 24, 2026 · 15:09 ET
Vertex Pharmaceuticals Gets 96% of Product Sales From Treatments for 1 Disease. Here's Why That's About to Change.

The biotech company has grown its annual revenue by more than 600% over the past decade. Kidney disease therapy inaxaplin is seen as a possible blockbuster drug.…

● Business WireOct 20, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Vertex Appoints Daniel Brennan to its Board of Directors

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Daniel Brennan has been appointed to its Board of Directors as an independent director. Mr. Brennan has more than 35 years …

● Business WireOct 20, 2026 · 09:00 ET
IGEN and Vertex Unite Excise and Global Indirect Tax in a Single Solution

APPLETON, Wis.--(BUSINESS WIRE)--IGEN, an industry leader in excise tax compliance automation, today announced an expansion of its strategic collaboration with Vertex, Inc., the Decision-to-Defense™ global indirect tax a…

● GlobeNewsWireOct 20, 2026 · 08:05 ETCOMPANY'S OWN WORDS
Vertex AI and Data Leader Sarah Vlasic Named a 2026 Info-Tech Women Leading IT Award Winner

Recognition highlights Vlasic's leadership of Vertex's enterprise AI and data transformation and her commitment to developing the next generation of women in technology Recognition highlights Vlasic's leadership of Verte…

● GlobeNewsWireOct 15, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Vertex to Announce Third Quarter 2026 Financial Results on Wednesday, November 4, 2026

KING OF PRUSSIA, Pa., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX),  the Decision-to-Defense™ global indirect tax and compliance company, today announced that it will release third quarter 2026 financial …

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

Article counts from the last market-wide feed page, across every symbol we track and not just VERX · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.